Dissertations / Theses on the topic 'BRCA testing'
To see the other types of publications on this topic, follow the link: BRCA testing.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 23 dissertations / theses for your research on the topic 'BRCA testing.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
1
Pack, Jessica K. B. A. "The Impact of the Myriad Direct-to-Consumer Advertising Campaign for BRCA1/2 Genetic Testing in the Greater Cincinnati Area." University of Cincinnati / OhioLINK, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1311692006.
Full text
2
Ferlatte, Christy. "Patient preferences for an appropriate time for cancer genetic counseling and BRCA testing for women diagnosed with breast cancer." Waltham, Mass. : Brandeis University, 2009. http://dcoll.brandeis.edu/handle/10192/23193.
Full text
3
Christopher, Juleen L. "An Examination of Dimensions of Perceived Behavioral Control Regarding Genetic Counseling and Testing for BRCA 1 and BRCA 2 in African-American Women at Moderate to High-Risk for Breast Cancer." Diss., Virginia Tech, 2010. http://hdl.handle.net/10919/77364.
Full textAbstract:
Breast cancer affects thousands of women each year and among those diagnosed, African-American women (AAW) make up a significant proportion that are diagnosed with early onset disease, have larger tumors, greater lymph node involvement, higher mortality and lower survival rates. Studies examining factors associated with greater breast cancer morbidity and mortality in this group have suggested that they may differ from Caucasian women in terms of certain risk factors for breast cancer; however, other evidence suggests that the risk of developing breast cancer is similar among African-American and Caucasian women who have a family history of breast cancer. As such, access to genetic counseling and testing (GC/T) services would be an important part of cancer control for this group but in this fast moving area of medicine African-American women are being "left behind".
It is unclear why AAW have not readily adopted these preventive services. In light of the paucity of evidence regarding explanations of underuse, it is possible that important factors such as perceived behavioral control (PBC) in the Theory of Planned Behavior may help explain African-American women's participation in genetic counseling and testing for BRCA 1/2. The goals of this mixed methods study were twofold; first, to explore levels of perceived behavioral control and general motivations regarding genetic counseling and testing for BRCA 1/2 in African-American women at moderate to high-risk for breast and ovarian cancer and second, to explore the dimensionality of the perceived behavioral control construct from the Theory of Planned Behavior (TPB) and its utility in understanding underuse of BRCA 1/2 genetics services in this group. African-American women are being "left behind".
Overall, women had high levels of perceived behavioral control, low knowledge and positive attitudes towards genetic counseling and testing for BRCA 1/2. Results from the principal components analysis lent support for the dimensionality of the perceived behavioral control construct suggesting that it indeed could be thought of as made up of the constructs perceived control [P-C] and perceived difficulty [P-D]. Only perceived control was found to be associated with genetic testing intentions suggesting that it was a better predictor. Neither scale was associated with genetic counseling intentions. African-American women are being "left behind".
Future research should focus on educational efforts geared towards highlighting the utility of genetic counseling in addition to genetic testing for BRCA 1/2. Theoretical implications include using two measures to assess aspects of perceived behavioral control (perceived difficulty [P-D] and perceived control [P-C]) instead of one PBC measure. Additionally, studies using the TPB model should include the constructs of spirituality and knowledge when trying to understand underuse of BRCA 1/2 genetic services in African-American women at moderate to high-risk for breast cancer. African-American women are being "left behind".Ph. D.
4
Chadwell, Sarah E. B. S. "Factors Influencing Clinical Follow-up for Individuals with a Personal History of Breast and/or Ovarian Cancer and Previous Negative or Uncertain BRCA1 and BRCA2 Testing." University of Cincinnati / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1491317215551797.
Full text
5
Elliott, Diana. "The impact of genetic counselling for familial breast cancer on women's psychological distress, risk perception and understanding of BRCA testing." University of Western Australia. School of Population Health, 2008. http://theses.library.uwa.edu.au/adt-WU2008.0190.
Full textAbstract:
[Truncated abstract] Background: A review of the literature indicated there was a need for more long-term randomised controlled studies on the effects of BRCA counselling/testing on high risk women, including improved strategies for risk communication. Reviews have also shown women are confused about the significance of inconclusive or non informative results with a need for more research in this area. Aims: The general aim of this study was to evaluate the impact of breast cancer genetic counselling on psychological distress levels, perception of risk, genetic knowledge and understanding of BRCA testing/test results in a cohort of 207 women from high risk breast cancer families who were referred for genetic counselling in Perth during the period 1997 to 2001. Short- and long-term impact of BRCA genetic counselling/testing was determined in women with and without cancer in a randomised controlled trial as part of which women were randomised to either receive immediate versus delayed genetic counselling. This included family communication patterns before BRCA testing, anticipated outcomes of testing on oneself and family including intentions for result disclosure. Comprehension of index and predictive BRCA testing with possible results was assessed both in the short- and the long-term and understanding of individual or family BRCA test results was evaluated at long-term. The effect of genetic counselling on breast cancer risk perception in unaffected women was evaluated. This study considered a theoretical framework of educational learning theories to provide a basis for risk communication with possible relevance for future research. ... Only 25% of the original study population (52/207) reported BRCA results and women's understanding of results is concerning. Key findings were: 1. The majority of affected women received an inconclusive result. 2. Out of twelve unaffected women who reported results, seven were inconclusive which are not congruent with predictive testing. This implies that these women did not understand their test result. 3. A minority of untested relatives did not know whether a family mutation had or had not been found in their tested family member or what their actual test result was. This implies either a lack of disclosure or that woman did not understand the rationale for and significance of testing for a family mutation. 4. Three relatives did not understand a positive result was a mutation. Conclusion: The implication of this research for breast cancer counselling and testing services is that women who wait for counselling are no worse off in terms of short- or long-term general psychological distress than women who receive the intervention early. There is a suggestion that unaffected women without the disease found counselling more advantageous than affected women. The meaning of BRCA results as reported by women is concerning particularly women's understanding of negative and inconclusive results and further research is needed in this area. Too much information presented at counselling may affect women's comprehension of risk, BRCA testing and future test results and further research is required to evaluate the effects of information overload.
6
Arver, Brita. "Hereditary breast/ovarian cancer : implementation of BRCA1 & BRCA2 testing /." Stockholm, 2001. http://diss.kib.ki.se/2001/91-628-4799-6/.
Full text
7
Keenan, Lisa A. "Family Environment, Social Support, and Psychological Distress of Women Seeking BRCA1 and BRCA2 Genetic Mutation Testing." Thesis, University of North Texas, 2002. https://digital.library.unt.edu/ark:/67531/metadc3240/.
Full textAbstract:
Shared characteristics and predictors of psychological distress are beginning to be identified in research on women seeking genetic testing for BRCA1 and BRCA2 gene mutations. This study further explored patterns of psychological distress for 51 community women waiting to receive such genetic test results. There was no significant relationship between psychological distress and family cancer history, personal cancer history, social support networks, and family environment. Women in this sample tended to rely more on females and relatives for support than males and friends. Social support satisfaction was not related to gender or number of relatives providing support. Thirty-four of the 36 women classified on the family environment type were from Personal Growth-Oriented families. Comparisons with normal and distressed family means revealed increased cohesion and expressiveness with decreased conflict, indicative of supportive family environments. Limitations and implications are discussed.
8
Doughty, Courtney R. "Retrospective Comparison of In-person versus Telephone Results Disclosure Counseling for BRCA1/2 Genetic Testing." University of Cincinnati / OhioLINK, 2008. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1211940755.
Full text
9
Lesniak, Karen. "Psychological and Sociodemographic Predictors of Psychological Distress in BRCA1 and BRCA2 Genetic Testing Participants within a Community Based Genetic Screening Program." Thesis, University of North Texas, 2000. https://digital.library.unt.edu/ark:/67531/metadc2565/.
Full textAbstract:
Mutations in BRCA1 and BRCA2, the first two breast cancer susceptibility genes identified, carry as much as an 85% lifetime risk of developing breast, ovarian or other cancers. Genetic testing for mutations in these two genes has recently become commercially available. There have been varying amounts of psychological distress noted among women with a family history of breast cancer. Distress has been observed to impact psychological functioning, activities of daily living, and the practice of breast cancer surveillance behaviors. Within the genetic screening process, psychological distress has been shown to impact the decision to undergo genetic screening, the comprehension and retention of risk assessment information, as well as affecting the subject following the receipt of the genetic test results. Little work has been done to examine predictors of distress within at risk subjects. This study examines psychological distress among 52 community women presenting for BRCA1 and BRCA2 genetic mutation testing. Predictors of distress included family cancer history, education, age, Ashkenazi ethnicity, and Internality and Powerful Others Health Locus of Control. Vulnerable sub-groups of patients include younger women, women with higher levels of education and women of Ashkenazi ethnicity.
10
Coltri, Julia Anne. "Transgender male patients and hereditary breast cancer risk: broaching difficult topics to reduce healthcare disparities." The Ohio State University, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=osu1555683611281611.
Full text
11
Bajdik, Christopher Douglas. "Family history of breast/ovarian cancer and referral criteria for a BRCA1 testing program." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2001. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/NQ61058.pdf.
Full text
12
Suzuki, Ayaka. "Familial Communication of Positive BRCA1/2 Genetic Testing Results: A Relational Dialectics Theory Approach." University of Cincinnati / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1504787059498275.
Full text
13
Chivers, Seymour Kimberley-Clair. "Talking to relatives about genetic testing for BRCA1/2 and its risk implications : an on-going discussion." Thesis, University of Southampton, 2013. https://eprints.soton.ac.uk/354118/.
Full textAbstract:
Background: Access to genetic cancer risk information can be highly dependent on whether familial risks are discussed within the family. Despite its essential role in ensuring family members have access to genetic services, there are a number of gaps in the knowledge available on people’s experiences regarding talking to their relatives about genetic testing for BRCA1/2 and its risk implications. In particular, research to date has focused far more on with whom and why (motivations) family communication regarding genetic testing occurs, rather than when or how it is occurring. Method: The study is qualitative in nature, employing in-depth interviews and constructing eco-maps as a method of identifying relevant family members and guiding the researcher through the family structure and relationships. These methods were chosen in line with an interpretive description methodology to ensure depth and richness in analysis and reporting of findings. Results: The Key Findings are as follows: 1. Communication between emotionally close relatives is different to communication with emotionally distant relatives; with emotionally close family and friends it is about sharing and supporting; whereas with emotionally distant family it is about gaining and imparting information. 2. A family’s engagement in communication regarding genetic testing is implicitly linked to their experiences of cancer burden, and how openly this is discussed in the family. 3. There is a lack of understanding of risks to men and their offspring based on perceptions of hereditary breast and ovarian cancer being a female disease. 4. Emotionally distant and male relatives are only contacted selectively. Those undergoing genetic testing for BRCA1/2 are not good at identifying all at-risk family members in order to share the implications of the genetic test with them. 5. As far as the family are concerned, members do not have the right to make an informed decision to decline. 6. Plans for telling people in the future, especially children, is a cause of worry and concern for those undergoing testing and needs further support, especially in the longer term. Conclusions: Developing interventions to help manage problems associated with family communication regarding genetic testing for cancer risk should be a top research priority, especially as the numbers of people affected by these issues is set to rise as more genes are discovered. The longitudinal view identified gives deep insight into how and when genetic testing for BRCA1/2 are discussed within these families, allowing future interventions to be targeted where they are most helpful.
14
Van, Tassel William Edward. "An evaluation of pocket-model, numerical readout breath alcohol testing instruments." Texas A&M University, 2003. http://hdl.handle.net/1969.1/1159.
Full textAbstract:
Eight small-scale breath alcohol measurement devices were tested for accuracy, precision and the ability to not yield false positive and false negative readings. These pocket-sized breath testers (PMBTs), which provided numerical readout of BrAC to the 100th of a percent, were smaller than evidential and preliminary breath test instruments (EBTs and PBTs). The smallest devices were approximately the same size of a cigarette lighter. Designed to provide drinkers feedback about their individual alcohol levels, the PMBTs ranged in price from $40-100 USD.
The devices were first tested under laboratory conditions with alcohol solution simulators providing the alcoholic samples. They were then tested with human drinkers, under controlled field conditions. Each device was tested at multiple alcohol levels.
Two of the eight PMBTs failed to complete all levels of testing and were excluded from the study. All PMBTs demonstrated the ability to not yield false positive and false negative readings. No device met NHTSA performance criteria for accuracy (systematic error) in testing EBTs at every alcohol level tested. An interaction between PMBTs and the alcohol test levels was found. Thus, accuracy was found to be dependent upon the alcohol level at which the devices were tested. No device met NHTSA performance criteria for precision in testing EBTs at every alcohol level tested. Precision varied depending on the testing condition. There was less precision under controlled field conditions than under laboratory conditions. Five of the six PMBTs that completed the testing overestimated BrAC; only one device read below actual BrAC.
Ramifications of the findings are discussed, regarding the overestimation and underestimation of BrAC and the possibility of manufacturers intentionally calibrating the devices to overestimate BrAC. Potential PMBT users are discussed and areas for future research are addressed.
15
Skates, Steven J., Mark H. Greene, Saundra S. Buys, Phuong L. Mai, Powel Brown, Marion Piedmonte, Gustavo Rodriguez, et al. "Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk-combined results from two screening trials." American Association for Cancer Research, 2017. http://hdl.handle.net/10150/625973.
Full textAbstract:
Purpose: Women at familial/genetic ovarian cancer risk often undergo screening despite unproven efficacy. Research suggests each woman has her own CA125 baseline; significant increases above this level may identify cancers earlier than standard 6-12 monthly CA125>35U/mL.
Experimental Design: Data from prospective Cancer Genetics Network and Gynecologic Oncology Group trials, which screened 3,692 women (13,080 woman-screening years) with a strong breast/ovarian cancer family history or BRCA1/2 mutations, were combined to assess a novel screening strategy. Specifically, serum CA125 q3 months, evaluated using a risk of ovarian cancer algorithm (ROCA), detected significant increases above each subject’s baseline, which triggered transvaginal ultrasound. Specificity and PPV were compared with levels derived from general population screening (specificity 90%, PPV 10%), and stage-at-detection was compared with historical high-risk controls.
16
Holmes, Christina Patrice. "You're armed, I think you're better armed, women's opinions of genetic counselling and testing for hereditary breast and ovarian cancer susceptibility (BRCA1)." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2000. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape2/PQDD_0009/MQ52793.pdf.
Full text
17
Gibbons, Deborah Kay. "“It's Not Only About Them:“ Female Family Members' Understanding of Indeterminate Negative BRCA1/2 Test Results." BYU ScholarsArchive, 2018. https://scholarsarchive.byu.edu/etd/7701.
Full textAbstract:
Genetic test results have important implications for close family members. Indeterminate negative results are the most common outcome of BRCA1/2 mutation testing. Little is known about family members' understanding of indeterminate negative BRCA1/2 test results. The purpose of this qualitative descriptive study was to investigate how daughters and sisters received and understood genetic test results as shared by their mothers or sisters. Participants included 81 women aged 40-74 with mothers or sisters previously diagnosed with breast cancer and who received indeterminate negative BRCA1/2 test results. Participants had never been diagnosed with breast cancer nor received their own genetic testing or counseling. This IRB approved study utilized semi-structured interviews administered via telephone. The research team developed descriptive codes, and NVIVO software was used during qualitative analysis. Participants reported low amounts of information shared with them. Most women described test results as negative and incorrectly interpreted the test to mean there was no genetic component to the pattern of cancer in their families. Only 7 of 81 women accurately described test results consistent with the meaning of an indeterminate negative result — meaning a genetic cause for cancer in their family could still exist. Our findings demonstrate that indeterminate negative genetic test results are not well understood by family members. Lack of understanding may lead to an inability to effectively communicate results to primary care providers and missed opportunities for prevention, screening and further genetic testing. We recommend providing family members letters they can share with their own primary care providers whenever genetic testing is performed.
18
Williams-Jones, Bryn. "Genetic testing for sale : implications of commercial BRCA testing in Canada." Thesis, 2002. http://hdl.handle.net/2429/13580.
Full textAbstract:
Ongoing research in the fields of genetics and biotechnology hold the promise of improved
diagnosis and treatment of genetic diseases, and potentially the development of individually
tailored pharmaceuticals and gene therapies. Difficulty, however, arises in determining how
these services are to be evaluated and integrated equitably into public health care systems
such as Canada's. The current context is one of increasing fiscal restraint on the part of
governments, limited financial resources being dedicated to health care, and rising costs for
new health care services and technologies. This has led to increasing public debate in the last
few years about how to reform public health care, and whether we should prohibit, permit or
perhaps even encourage private purchase of health care services.
In Canada, some of these concerns have crystallized around the issue of gene patents and
commercial genetic testing, in particular as illustrated by the case of Myriad Genetics'
patented BRACAnalysis test for hereditary breast and ovarian cancer. While most Canadians
who currently access genetic services do so through the public health care system, for those
with the means, private purchase is becoming an option. This situation raises serious
concerns - about justice in access to health care; about continued access to safe and reliable
genetic testing supported by unbiased patient information; and about the broader effects of
commercialization for ongoing research and the Canadian public health care system.
Commercial genetic testing presents a challenge to health care professionals, policy analysts,
and academics concerned with the social, ethical and policy implications of new genetic
technologies. Using the Myriad case as an exemplar, tools from moral philosophy, the social
sciences, and health policy and law will be brought to bear on the larger issues of how as a
society we should regulate commercial research and product development, and more
coherently decide which services to cover under public health insurance and which to leave
to private purchase. Generally, the thesis is concerned with the question of "how best to bring
capital, morality, and knowledge into a productive and ethical relationship" (Rabinow 1999,
20).
19
Maheu, Christine. "Interpreting and making sense of uninformative results of testing for BRCA 1 and BRCA 2 cancer gene mutations." Thesis, 2005. http://hdl.handle.net/2429/17030.
Full textAbstract:
Research suggests that a significant proportion of individuals from families at risk of
hereditary breast and ovarian cancer will be found not to have a detectable mutation in their
BRCA1 or BRCA2 cancer genes. Although the interpretation of genetic test results is relatively
straightforward in families where a mutation has already been identified, little is known about
how people who have had breast and/or ovarian cancer in the past as well as a family history of
cancer considered at risk for HBOC interpret and make sense of test results concluding that no
detectable mutation has been found. This problem is further compounded when they are told that
such genetic test results do not completely rule out an inherited mutation because of their strong
family history of the disease. While the clinical and research literature refers to these results as
uninformative or inconclusive, this study shows that clients' interpretations are much more
complex. To date, few studies have focused on affected individuals from families at risk of
HBOC who receive uninformative genetic test results. We therefore have little knowledge of
how these individuals interpret and make sense of such results and how these results affect their
everyday lives, health and illness experiences.
This dissertation addresses these lacunae by using an interpretive description approach to
examine clients' experiences of genetic testing. Qualitative, in-depth interviews were conducted
with 21 affected individuals with a family history of cancer considered at risk for HBOC who
received genetic testing and 15 family members. The interview data show that living with a
personal and family history of breast and/or ovarian cancer plays an important role in
interpreting and then making sense of their genetic test results and in one's perception of
probably having an inherited mutation for HBOC. Thirteen generic structures were found to
organise beliefs towards the making sense process of interpreting their genetic test results while
three types of interpretation of the test results were derived from the participants' accounts. The
categories of interpretation are seeing results as: a confirmation of their mutation status,
ambiguity regarding their mutation status, and refutation of being a mutation carrier. On the basis
of these generic structures and the three types of interpretation, it is possible to see a
retrospective narrative of causal reasoning of having a probable inherited mutation that builds
upon recognition of a strong family history with breast and/or ovarian cancer. This 7-stage
process evolves with changes in people's everyday lives, health and illness experiences.
The impact of receiving uninformative test results for BRCA1 and BRCA2 mutations on
the lives of affected individuals and their family members requires further examination. We need
to understand how such results affect cancer and genetic risk perception and potentially
contribute to clients' viewing themselves at chronic risk of cancer and of an inherited mutation.
Further investigation is also needed to determine how uncertain genetic risk information is
shared among and used by family members. This dissertation offers recommendations to
ameliorate the experience of individuals who receive uninformative genetic test results, to
improve genetic testing services, and to enhance the genetic knowledge of nurses and their
clients.Applied Science, Faculty of
Nursing, School of
Graduate
20
Ozakinci, Gozde. "Psychological and behavioral outcomes of genetic testing for BRCA1/2 mutations among Ashkenazi Jewish Women /." 2004. http://wwwlib.umi.com/dissertations/fullcit/3153612.
Full text
21
Moura, Ana Luísa Pinto da Silva Lobo Peixoto de. "Spectrum of BRCA1 and BRCA2 germline mutations in Portuguese Hereditary Breast and Ovarian cancer: ancestral origin of founder mutations and their implications for genetic testing criteria and strategy." Tese, 2019. https://hdl.handle.net/10216/122595.
Full text
22
Moura, Ana Luísa Pinto da Silva Lobo Peixoto de. "Spectrum of BRCA1 and BRCA2 germline mutations in Portuguese Hereditary Breast and Ovarian cancer: ancestral origin of founder mutations and their implications for genetic testing criteria and strategy." Doctoral thesis, 2019. https://hdl.handle.net/10216/122595.
Full text
23
Magro, Tatiana Natália Tavares. "Testing the combinatory use of PARP1 and RPA inhibitors in breast cancer cell lines." Master's thesis, 2019. http://hdl.handle.net/10773/29527.
Full textAbstract:
Loss of tumor suppressor BRCA2 is strongly associated to breast cancer. BRCA2 is essential to homologous recombination (HR), which is a DNA repair pathway crucial to genomic stability. When cells become mutant for BRCA2, they cannot repair DNA damage through homologous recombination, which is an accurate repair pathway, and instead, rely on alternative error-prone pathways for DNA repair. Tumor cells mutant for BRCA2 become therefore dependent on these alternative repair pathways for survival.
The most recent generation of targeted therapies for breast cancer is PARP1 inhibitors. PARP1 is a protein essential to the initiation of several DNA repair pathways, including those alternative repair pathways, like the non-homologous end joining (NHEJ). The use of these inhibitors compromises the alternative pathways leading to tumor cell death. Though tumor cells mutant for BRCA2 are particularly sensitive to PARP1 inhibitors, the onset of tumor resistance has been frequently observed after long-term treatments. This motivated us to find alternative proteins whose inhibition specifically impaired, similar to PARP1, tumor cells viability and/or growth.
It was recently reported that BRCA2 regulates RNA polymerase II transcription and prevents the formation of R-loops, which are 3-strand nucleic acid structures composed of DNA:RNA hybrids. Accumulation of these R-loops is implicated in the process of carcinogenesis due to the accumulation of single-stranded DNA (ssDNA) and increased genomic instability. RPA is a ssDNA-binding protein whose function is crucial to protect ssDNA and avoid forming secondary structures, being crucial to DNA replication and DNA repair.
Our objective is to identify novel druggable targets whose inhibition can be used in combination or as an alternative to PARP1 inhibitors, minimizing tumor resistance risk. Our working hypothesis is that combinatory inhibition of PARP1 and RPA will specifically increase the loss of breast cancer cells viability.A perda do supressor tumoral BRCA2 está fortemente associada ao cancro da mama. O BRCA2 é essencial para a recombinação homóloga, que é uma via de reparação de ADN crucial para a estabilidade genómica. Quando as células sofrem mutações neste gene, elas não conseguem reparar os danos no ADN através da recombinação homóloga, que é uma via de reparação precisa, e em vez disso, tornam-se dependentes de vias alternativas, propensas a erros, para reparação de ADN. Deste modo, as células tumorais mutantes para BRCA2 tornam-se dependentes destas vias alternativas para sobreviverem. A geração mais recente de terapias direcionadas são os inibidores da PARP1. A PARP1 é uma proteína essencial para a iniciação de várias vias de reparação de ADN, incluindo as tais vias de reparação alternativas, como a non-homologous end joining (NHEJ). A utilização destes inibidores compromete as vias alternativas levando à morte das células tumorais. Embora as células tumorais mutantes para BRCA2 sejam particularmente sensíveis aos inibidores da PARP1, o aparecimento da resistência tumoral tem sido observado frequentemente após tratamentos de longo-prazo. Este problema motivou-nos a procurar proteínas alternativas cuja inibição prejudicasse especificamente, à semelhança da PARP1, a viabilidade e/ou crescimento das células tumorais. Foi recentemente reportado que o BRCA2 regula a transcrição da ARN polimerase II e previne a formação de R-loops, que são estruturas de ácidos nucleicos de 3 cadeias compostas por híbridos de ADN:ARN. A acumulação destes R-loops está implicada no processo de carcinogénese devido à acumulação de ADN de cadeia simples (do inglês ssDNA) e ao aumento de instabilidade genómica. O RPA é uma proteína que se liga ao ssDNA e evita que se formem estruturas secundárias, sendo crucial para a replicação e reparação de ADN. O nosso objetivo é identificar novos alvos terapêuticos cuja inibição possa ser usada em combinação ou como alternativa aos inibidores da PARP1, minimizando o risco de resistência tumoral. A nossa hipótese de trabalho é que a inibição combinatória de PARP1 e RPA aumentará especificamente a perda de viabilidade das células de cancro da mama.
Mestrado em Biomedicina Molecular